A Phase Ⅱ Study of an All-Oral Combination of Low-dose Etoposide/Capecitabine in Patients With Metastatic Breast Cancer Previously Treated With Anthracyclines and/or Taxanes

• Status: Completed
• Trial end date: 2016-12-01
• Target enrollment: 0
• Participant gender: Female

Summary

This is a single-center, open-lable, non-comparative, prospective, phase Ⅱ efficacy and safety study. Eligible patients are enrolled in a single group. The investigators propose to determine the efficacy and safety of low-dose metronomic chemotherapy with Etoposide/Capecitabine in Patients with Metastatic Breast Cancer Previously Treated with Anthracyclines and/or Taxanes.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Tao OUYANG
• Treatments: Capecitabine; Etoposide; Etoposide phosphate; Taxane

Criteria

Inclusion Criteria:

• female patients between 18 and 65 years old

• patients with metastatic breast cancer previousely treated with A/T

• able and willing to give consent to participate in the study

Exclusion Criteria:

• pregnant or lactating females

• other tumor history

• instable complication (e.g., myocardial infarction within 6 months,arrhythmia, unstable diabetes, hypercalcemia) or uncontrolled infection

• concurrent disease or condition that would make the patient inappropriate for study participation

• resist to participate in the study